98 completed, 3 withdrawn, 1 terminated. 102 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 102 | Completed 98, Withdrawn 3, Terminated 1 |
Follow AIDS-Related Complex: new trials by email Literature Review of AIDS-Related Complex trials Research Report on AIDS-Related Complex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2 - Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | Nordic Nanovector | 2017-12-19 | 2019-01-10 | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) Betalutin - Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | Nordic Nanovector | 18 | 2017-03-02 | 2024-01-16 |
| A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients. Peptide T - HIV Infections | Phase 1 | Completed | National Institute of Mental Health (NIMH) | 30 | 1988-01-01 | 2015-03-03 |
| A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects Ampligen - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2021-11-03 | |
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns CD4-IgG - HIV Infections, Pregnancy | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2005-06-24 | |
| A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss Nandrolone decanoate - HIV Infections, HIV Wasting Syndrome | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 38 | 2021-10-29 | |
| Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human) Anti-HIV Immune Serum Globulin (Human) - HIV Infections | Phase 1 | Completed | Abbott | 12 | 2009-02-20 | |
| A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC) Zidovudine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 12 | 2021-11-03 | |
| An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3) Nevirapine, Zidovudine - HIV Infections | Phase 1 | Completed | Boehringer Ingelheim | 30 | 2008-07-30 | |
| A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC Atevirdine mesylate, Zidovudine, Zalcitabine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2021-11-04 | |
| A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children Aldesleukin - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 27 | 2021-10-29 | |
| Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo) MF59, rgp120/HIV-1 SF-2 - HIV Infections, Pregnancy | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-01 | ||
| A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex CD4 Antigens - HIV Infections | Phase 1 | Completed | Genentech, Inc. | 2005-06-24 | ||
| A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects Hypericin - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2021-11-04 | |
| A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant) - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 55 | 2021-11-02 | |
| Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex Butyldeoxynojirimycin - HIV Infections | Phase 1 | Completed | G D Searle | 48 | 2005-06-24 | |
| A Study of Dextran Sulfate in HIV-Infected Patients and in Patients With AIDS or AIDS Related Complex (ARC) Dextran sulfate - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 60 | 2021-11-01 | |
| A Phase I Study of Methotrexate for HIV Infection Lamivudine, Methotrexate, Zidovudine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2021-10-29 | |
| An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive CD4 Antigens - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 85 | 2021-10-28 | |
| A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection Ro 24-7429, Zidovudine, Didanosine - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 96 | 2008-08-04 |
Showing 20 of 102. Sign in to see all of them.
HIV Infections (100) · Acquired Immunodeficiency Syndrome (89) · AIDS-Related Opportunistic Infections (4) · Pneumonia, Pneumocystis (4) · Pregnancy Complications, Infectious (4) · Chickenpox (2) · Cytopenia (2) · HIV Seropositivity (2) · Immune System Diseases (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2)
Blood-Borne Infections (102) · Communicable Diseases (102) · Genital Diseases (102) · Immunologic Deficiency Syndromes (102) · Infections (102) · Lentivirus Infections (102) · RNA Virus Infections (102) · Retroviridae Infections (102) · Sexually Transmitted Diseases (102) · Sexually Transmitted Diseases, Viral (102) · Slow Virus Diseases (102) · Urogenital Diseases (102) · Virus Diseases (102) · Immune System Diseases (100) · Bacterial Infections and Mycoses (8)
Zidovudine (28) · Didanosine (14) · aldesleukin (7) · Nevirapine (4) · Ribavirin (4) · Interferon alpha-2 (3) · Stavudine (3) · Zalcitabine (3) · CD4 Antigens (2) · CD4 Immunoadhesins (2) · Dapsone (2) · Fluconazole (2) · Foscarnet (2) · Lutetium (2) · MF59 oil emulsion (2)
National Institute of Allergy and Infectious Diseases (NIAID) (72) · Gilead Sciences (4) · AJI Pharma USA (2) · Argus Pharmaceuticals (2) · Glaxo Wellcome (2) · Merck Sharp & Dohme LLC (2) · Nordic Nanovector (2) · Aaron Diamond AIDS Research Center (1) · Abbott (1) · Amgen (1) · Boehringer Ingelheim (1) · Chiron Corporation (1) · Columbia Research Laboratories (1) · G D Searle (1) · Genentech, Inc. (1)
United States (99) · Puerto Rico (12) · Germany (2) · Italy (1) · Spain (1) · United Kingdom (1)
Crumpacker C (3) · M Ho (3) · Merigan TC (3) · Schooley RT (3) · Bartlett JA (2) · Reichman R (2) · Richman DD (2) · Scott GB (2) · Unadkat J (2) · Valentine FT (2) · Van Dyke R (2) · Walker B (2) · A Collier (1) · A Kovacs (1) · Abrams D (1)